CN106727890A - A kind of pharmaceutical composition for treating fatty liver - Google Patents
A kind of pharmaceutical composition for treating fatty liver Download PDFInfo
- Publication number
- CN106727890A CN106727890A CN201611253386.2A CN201611253386A CN106727890A CN 106727890 A CN106727890 A CN 106727890A CN 201611253386 A CN201611253386 A CN 201611253386A CN 106727890 A CN106727890 A CN 106727890A
- Authority
- CN
- China
- Prior art keywords
- parts
- fatty liver
- pharmaceutical composition
- treatment
- silymarin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for treating fatty liver, the pharmaceutical composition of the treatment fatty liver is according to the primary raw material of weight portion：6 22 parts of cassia seed, 0.2 0.6 parts of D tryptophans, 2 10 parts of carrotene, 0.2 0.7 parts of geraniin, 10 20 parts of Glucurolactone, 37 parts of the membrane of a chicken's gizzard, 0.9 1.5 parts of dendrobine, 0.2 0.5 parts of Sodium Danshensu, 46 parts of Ethyl p-methoxy-silicate, 13 parts of silymarin.Medicine of the present invention significantly improves Patients with Fatty Liver symptom and Signs, can substantially adjust blood lipid metabolism effect, and with good effect, short treating period, price is low, the features such as having no toxic side effect substantially, has the value of popularization and application in terms of fatty liver is treated.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of pharmaceutical composition for treating fatty liver.
Background technology
Fat accounts for the 3%~5% of liver gross weight under normal circumstances.When fat content exceedes 1/10 or group of liver weight
As fatty liver when knitting upper liver cell Steatosis more than half.Its pathogenesis is not yet completely clear and definite so far, it is considered that
The imbalance that liver cell synthesizes between triacylglycerol and secretion VLDL is the main cause to form fatty liver, and this
It is caused by liver cell Fatty synthesis increase or oxidation is reduced to plant imbalance.With habits and customs and the change of dietary structure,
The enhancing of health care consciousness, the progress of detection means, the incidence of disease and recall rate of fatty liver gradually increase, it has also become a serious danger
The healthy common hidden danger of victimization class, certain areas fatty liver has turned into the second largest hepatopathy for being only second to virus hepatitis.According to
American-European scholar's statistics, pathogenesis of fatty liver rate accounts for 10%~24%, 57.5%~74% is accounted in overweight people in population.At me
State, according to the part investigation result in the area such as Beijing, Shanghai and Nanjing, Hangzhou, Lianyungang of Jiangsu, the incidence of disease is 5.2%~11.4%
Between, wherein male is higher than women, and age of onset has less and less trend.It is appreciated that studies have found that
The incidence of NASH (NAFL) liver fibrosis is up to 25%.Wherein 1.5%~8.0% patient can progress to liver
Cirrhosis, and cause a series of severe complications, it is considered to be the common disease factor of hidden source property cirrhosis.Therefore, lipotropism is got over
Cause the attention of people to get over.There is different degrees of toxicity in current western medicine fatty liver, or lipid-lowering effect it is undesirable and
Can often be rebounded after drug withdrawal and affected the treatment, therefore for fatty liver such a chronic disease, control the fiber of its development and liver
Change aspect is restricted.The fatty liver traditional Chinese medical science belongs to categories such as " accumulation " " fat gas " more without this name of disease, belongs to the disease of liver spleen, as
《Interior warp》Institute's cloud：" product of liver, day fat gas ".Think that the disease is insobriety or sitting of crouching long due to long-term addiction delicious food savoury,
The rich phlegm of body is full of, or inernal injuries caused by seven emotions, and it is improper to take good care of oneself, and spleen weakness, liver dysfunction, organism metabolic disorder, water paddy is unable to metaplasia essence
It is micro-, it is poly- and be it is wet be phlegm, stasis blocking liver network and form the disease.Chinese medicine fatty liver curative effect is steady, have the advantage of multidirectional regulation,
Research in recent years to traditional Chinese herbal decoction treatment fatty liver is more.So far, for the treatment of fatty liver, in the traditional Chinese medical science and doctor trained in Western medicine side
The therapeutic scheme being entirely satisfactory is not found in face.
The pathogenesis of fatty liver is not yet completely clear and definite so far, it is considered that liver cell synthesizes triacylglycerol and secretes low close
Imbalance between degree lipoprotein is the main cause to form fatty liver.Therefore, it is badly in need of a kind of suitable good effect of research and development, speed
Hurry up, price is low, the Western medicine compound that has no toxic side effect.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating fatty liver, to solve to be carried in above-mentioned background technology
The problem for going out.
To achieve the above object, the present invention provides following technical scheme：
A kind of pharmaceutical composition for treating fatty liver, be according to the primary raw material of weight portion：Cassia seed 6-22 parts, D- color ammonia
Sour 0.2-0.6 parts, carrotene 2-10 parts, geraniin 0.2-0.7 parts, Glucurolactone 10-20 parts, the membrane of a chicken's gizzard 3-7 parts, the stem of noble dendrobium
Alkali 0.9-1.5 parts, Sodium Danshensu 0.2-0.5 parts, Ethyl p-methoxy-silicate 4-6 parts, silymarin 1-3 parts.
As further scheme of the invention：The pharmaceutical composition of the treatment fatty liver, according to the main original of weight portion
Expect be：Cassia seed 11-16 parts, D-trp 0.4-0.5 parts, carrotene 5-7 parts, geraniin 0.3-0.6 parts, Glucurolactone
12-17 parts, the membrane of a chicken's gizzard 4-6 parts, dendrobine 1.2-1.4 parts, Sodium Danshensu 0.2-0.5 parts, Ethyl p-methoxy-silicate 4-6
Part, silymarin 1-3 parts.
As further scheme of the invention：The pharmaceutical composition of the treatment fatty liver, according to the main original of weight portion
Expect be：14 parts of cassia seed, 0.5 part of D-trp, 6 parts of carrotene, 0.5 part of geraniin, 15 parts of Glucurolactone, the membrane of a chicken's gizzard 5
Part, 1.3 parts of dendrobine, 0.4 part of Sodium Danshensu, 5 parts of Ethyl p-methoxy-silicate, 2 parts of silymarin.
A kind of preparation method of the pharmaceutical composition for treating fatty liver, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cassia seed, D-trp, carrotene, geranium wilfordii are weighed by above-mentioned metering ratio
Element, Glucurolactone, the membrane of a chicken's gizzard, dendrobine, Sodium Danshensu, Ethyl p-methoxy-silicate, silymarin, sieving, machinery are mixed
After add ultra-pure water, place in pharmacy mixer, mix 2-10min, control RSD≤5%, compressing tablet and low temperature drying after mixing,
At 10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of fatty liver to temperature control.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention significantly improves Patients with Fatty Liver symptom and Signs, blood lipid metabolism effect can be substantially adjusted, with treatment
Imitate, short treating period, price is low, the features such as having no toxic side effect substantially, there is the value of popularization and application in terms of fatty liver is treated.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of pharmaceutical composition for treating fatty liver, be according to the primary raw material of weight portion：8 parts of cassia seed, D-trp
0.2 part, 4 parts of carrotene, 0.2 part of geraniin, 10 parts of Glucurolactone, 3 parts of the membrane of a chicken's gizzard, 0.9 part of dendrobine,
0.2 part of Sodium Danshensu, 4 parts of Ethyl p-methoxy-silicate, 1 part of silymarin.
A kind of preparation method of the pharmaceutical composition for treating fatty liver, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cassia seed, D-trp, carrotene, geranium wilfordii are weighed by above-mentioned metering ratio
Element, Glucurolactone, the membrane of a chicken's gizzard, dendrobine, Sodium Danshensu, Ethyl p-methoxy-silicate, silymarin, sieving, machinery are mixed
After add ultra-pure water, place in pharmacy mixer, mix 4min, control RSD≤5%, compressing tablet and low temperature drying, temperature after mixing
At 10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of fatty liver for control.
Embodiment 2
A kind of pharmaceutical composition for treating fatty liver, be according to the primary raw material of weight portion：11 parts of cassia seed, D-trp
0.4 part, 5 parts of carrotene, 0.3 part of geraniin, 12 parts of Glucurolactone, 4 parts of the membrane of a chicken's gizzard, 1.2 parts of dendrobine, Sodium Danshensu 0.2
Part, 4 parts of Ethyl p-methoxy-silicate, 1 part of silymarin.
A kind of preparation method of the pharmaceutical composition for treating fatty liver, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cassia seed, D-trp, carrotene, geranium wilfordii are weighed by above-mentioned metering ratio
Element, Glucurolactone, the membrane of a chicken's gizzard, dendrobine, Sodium Danshensu, Ethyl p-methoxy-silicate, silymarin, sieving, machinery are mixed
After add ultra-pure water, place in pharmacy mixer, mix 4min, control RSD≤5%, compressing tablet and low temperature drying, temperature after mixing
At 10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of fatty liver for control.
Embodiment 3
A kind of pharmaceutical composition for treating fatty liver, be according to the primary raw material of weight portion：14 parts of cassia seed, D-trp
0.5 part, 6 parts of carrotene, 0.5 part of geraniin, 15 parts of Glucurolactone, 5 parts of the membrane of a chicken's gizzard, 1.3 parts of dendrobine, Sodium Danshensu 0.4
Part, 5 parts of Ethyl p-methoxy-silicate, 2 parts of silymarin.
A kind of preparation method of the pharmaceutical composition for treating fatty liver, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cassia seed, D-trp, carrotene, geranium wilfordii are weighed by above-mentioned metering ratio
Element, Glucurolactone, the membrane of a chicken's gizzard, dendrobine, Sodium Danshensu, Ethyl p-methoxy-silicate, silymarin, sieving, machinery are mixed
After add ultra-pure water, place in pharmacy mixer, mix 6min, control RSD≤5%, compressing tablet and low temperature drying, temperature after mixing
At 10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of fatty liver for control.
Embodiment 4
A kind of pharmaceutical composition for treating fatty liver, be according to the primary raw material of weight portion：16 parts of cassia seed, D-trp
0.5 part, 7 parts of carrotene, 0.6 part of geraniin, 17 parts of Glucurolactone, 6 parts of the membrane of a chicken's gizzard, 1.4 parts of dendrobine, Sodium Danshensu 0.5
Part, 6 parts of Ethyl p-methoxy-silicate, 3 parts of silymarin.
A kind of preparation method of the pharmaceutical composition for treating fatty liver, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cassia seed, D-trp, carrotene, geranium wilfordii are weighed by above-mentioned metering ratio
Element, Glucurolactone, the membrane of a chicken's gizzard, dendrobine, Sodium Danshensu, Ethyl p-methoxy-silicate, silymarin, sieving, machinery are mixed
After add ultra-pure water, place in pharmacy mixer, mix 8min, control RSD≤5%, compressing tablet and low temperature drying, temperature after mixing
At 10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of fatty liver for control.
Embodiment 5
A kind of pharmaceutical composition for treating fatty liver, be according to the primary raw material of weight portion：20 parts of cassia seed, D-trp
0.6 part, 8 parts of carrotene, 0.7 part of geraniin, 20 parts of Glucurolactone, 7 parts of the membrane of a chicken's gizzard, 1.5 parts of dendrobine, Sodium Danshensu 0.5
Part, 6 parts of Ethyl p-methoxy-silicate, 3 parts of silymarin.
A kind of preparation method of the pharmaceutical composition for treating fatty liver, concretely comprises the following steps：
First, in pharmaceutical grade clean area, cassia seed, D-trp, carrotene, geranium wilfordii are weighed by above-mentioned metering ratio
Element, Glucurolactone, the membrane of a chicken's gizzard, dendrobine, Sodium Danshensu, Ethyl p-methoxy-silicate, silymarin, sieving, machinery are mixed
After add ultra-pure water, place in pharmacy mixer, mix 8min, control RSD≤5%, compressing tablet and low temperature drying, temperature after mixing
At 10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of fatty liver for control.
It should be understood that, although the present specification is described in terms of embodiments, but not each implementation method only includes one
Individual independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art will should say
Used as an entirety, technical scheme in each embodiment can also be through appropriately combined, and forming those skilled in the art can be with for bright book
The other embodiment of understanding.
Claims (5)
1. a kind of pharmaceutical composition for treating fatty liver, it is characterised in that the primary raw material according to weight portion is：Cassia seed 6-22
Part, D-trp 0.2-0.6 parts, carrotene 2-10 parts, geraniin 0.2-0.7 parts, Glucurolactone 10-20 parts, the membrane of a chicken's gizzard 3-
7 parts, dendrobine 0.9-1.5 parts, Sodium Danshensu 0.2-0.5 parts, Ethyl p-methoxy-silicate 4-6 parts, silymarin 1-3 parts.
2. it is according to claim 1 treatment fatty liver pharmaceutical composition, it is characterised in that the medicine of the treatment fatty liver
Compositions, be according to the primary raw material of weight portion：Cassia seed 11-16 parts, D-trp 0.4-0.5 parts, carrotene 5-7 parts,
Geraniin 0.3-0.6 parts, Glucurolactone 12-17 parts, the membrane of a chicken's gizzard 4-6 parts, dendrobine 1.2-1.4 parts, Sodium Danshensu 0.2-0.5
Part, Ethyl p-methoxy-silicate 4-6 parts, silymarin 1-3 parts.
3. it is according to claim 1 and 2 treatment fatty liver pharmaceutical composition, it is characterised in that the treatment fatty liver
Pharmaceutical composition, be according to the primary raw material of weight portion：14 parts of cassia seed, 0.5 part of D-trp, 6 parts of carrotene, old stork
Careless 0.5 part of element, 15 parts of Glucurolactone, 5 parts of the membrane of a chicken's gizzard, 1.3 parts of dendrobine, 0.4 part of Sodium Danshensu, Ethyl p-methoxy-silicate
5 parts, 2 parts of silymarin.
4. the preparation method of the pharmaceutical composition of a kind for the treatment of fatty liver as described in claim 1-3 is any, it is characterised in that
Concretely comprise the following steps：
First, in pharmaceutical grade clean area, cassia seed, D-trp, carrotene, geraniin, Portugal are weighed by above-mentioned metering ratio
Aldehyde lactone, the membrane of a chicken's gizzard, dendrobine, Sodium Danshensu, Ethyl p-methoxy-silicate, silymarin, sieving, machinery are added after mixing
Ultra-pure water, places in pharmacy mixer, mixes 2-10min, controls RSD≤5%, compressing tablet and low temperature drying, temperature control after mixing
At 10 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of fatty liver to system.
5. it is according to claim 4 treatment fatty liver pharmaceutical composition preparation method, it is characterised in that specific steps
Middle mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611253386.2A CN106727890A (en) | 2016-12-30 | 2016-12-30 | A kind of pharmaceutical composition for treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611253386.2A CN106727890A (en) | 2016-12-30 | 2016-12-30 | A kind of pharmaceutical composition for treating fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727890A true CN106727890A (en) | 2017-05-31 |
Family
ID=58953141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611253386.2A Pending CN106727890A (en) | 2016-12-30 | 2016-12-30 | A kind of pharmaceutical composition for treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727890A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117860678A (en) * | 2024-03-13 | 2024-04-12 | 中国农业大学 | Pharmaceutical composition for treating alcoholic fatty liver and preparation method thereof |
-
2016
- 2016-12-30 CN CN201611253386.2A patent/CN106727890A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117860678A (en) * | 2024-03-13 | 2024-04-12 | 中国农业大学 | Pharmaceutical composition for treating alcoholic fatty liver and preparation method thereof |
| CN117860678B (en) * | 2024-03-13 | 2024-05-28 | 中国农业大学 | Pharmaceutical composition for treating alcoholic fatty liver and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105535679A (en) | Probiotic enzyme ecological-restoration composition | |
| CN102172269B (en) | Hidegelatin fabricated food with beautification function | |
| CN102008412A (en) | Skin care composition with whitening efficacy, preparation and preparation method thereof | |
| CN105412623A (en) | Medicament for treating fatty liver, prostatitis, nephralgia, nephritis, hypertension and diabetes | |
| CN103300358A (en) | Health care product capable of improving immunity | |
| CN101032599B (en) | Healthy solution for conditioning skin and losing weight | |
| CN106727890A (en) | A kind of pharmaceutical composition for treating fatty liver | |
| Kamohara et al. | Safety of a Coleus forskohlii formulation in healthy volunteers | |
| CN102430076A (en) | Umbilici-applied weight-reducing powder | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN101284096A (en) | Sheep placenta capsule compound nest-defence capsule for beautifying face | |
| CN105796604A (en) | Plaster and preparation method thereof | |
| CN105078823A (en) | Weight-reducing composition and preparation method thereof | |
| CN102552551B (en) | Chinese medicinal composition for losing weight and slimming and preparation thereof | |
| CN106727647A (en) | A kind of medicine for treating fatty liver | |
| Kamohara | An evidence-based review: Anti-obesity effects of Coleus forskohlii | |
| CN101020013A (en) | Hypoglycemic and antilipemic health product and its prepn | |
| CN106420784A (en) | Medicinal composition for treating fatty liver | |
| CN103156106A (en) | Lipid lowering and liver protecting drug or health food prepared by active ingredients of fructus schisandrae chinensis and preparation method | |
| CN104644660A (en) | Application of 20(R)-ginsenoside Rg3 in preparation of medicament for relieving or/and treating fatty liver | |
| CN102755444A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN107375771A (en) | A kind of medicine for weight-reducing and preparation method thereof | |
| CN102908437A (en) | Chinese medicinal soft capsule | |
| CN104771341B (en) | A kind of Chinese herb bath agent and preparation method thereof | |
| Xiaoying et al. | Potential role of Natural Herbal Tea as a healthy beverage in reducing the risk of liver cancer and chronic liver disease mortality |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |